Anderson Rudolf, Schmidt Rene
Department of Anesthesiology and Critical Care Medicine, University Medical Center, Freiburg, Germany.
Front Biosci (Elite Ed). 2010 Jan 1;2(2):504-20. doi: 10.2741/e109.
Sepsis is one of the leading causes of death in intensive care medicine in western countries. A strong body of evidence has been accumulated indicating that immediate resuscitation and restoration of tissue perfusion as well as early antibiotic treatment could significantly decrease the mortality in these patients. The clinical definitions of sepsis are basically nonspecific, often resulting in the delay of the diagnosis. Therefore, identification of specific clinical biomarkers may accelerate the diagnosis and thus improve sepsis treatment. During the last decade, a variety of different molecules have been proposed as clinical biomarkers in sepsis, most of which are still in the experimental stage. However, some have found their way into clinical practice and have evolved as valuable tools for diagnosis, therapy monitoring, and outcome prediction. This review will summarize the currently most important biomarkers and will discuss their clinical relevance.
脓毒症是西方国家重症监护医学中主要的死亡原因之一。大量证据表明，立即进行复苏和恢复组织灌注以及早期抗生素治疗可显著降低这些患者的死亡率。脓毒症的临床定义基本上不具有特异性，常常导致诊断延迟。因此，识别特定的临床生物标志物可能会加速诊断，从而改善脓毒症的治疗。在过去十年中，多种不同分子被提议作为脓毒症的临床生物标志物，其中大多数仍处于实验阶段。然而，一些已进入临床实践，并已发展成为诊断、治疗监测和预后预测的有价值工具。本综述将总结目前最重要的生物标志物，并讨论它们的临床相关性。
